论文部分内容阅读
糖尿病早期肾病患者40例,随机分成(每组20例):贝那普利联合前列腺素E1组,贝那普利联合阿托伐他汀组。观察治疗3周。结果两组均能减少UAER(P均<0.05),但贝那普利联合前列腺素E1组降低UAER更明显。TG和Tch均有不同程度的降低,但贝那普利联合阿托伐他汀组更明显(P<0.05)。结论贝那普利联合前列腺素E1治疗早期糖尿病肾病能更有效地降低UAER;贝那普利联合阿托伐他汀则降低Tch、TG更明显,提示临床治疗早期糖尿病肾病时,可将贝那普利、前列腺素E1和阿托伐他汀三药联合应用。
Forty diabetic patients with early nephropathy were randomly divided into two groups (20 in each group): benazepril combined with prostaglandin E1 group and benazepril combined with atorvastatin group. Observation and treatment for 3 weeks. Results Both groups were able to reduce UAER (all P <0.05). However, the decrease of UAER in benazepril combined with prostaglandin E1 group was more obvious. TG and Tch decreased to some extent, but benazepril combined with atorvastatin group was more obvious (P <0.05). Conclusion Berenopril combined with prostaglandin E1 can reduce UAER more effectively in patients with early diabetic nephropathy; benazepril combined with atorvastatin reduces Tch more significantly, suggesting that benazepril can be used to treat early diabetic nephropathy Lee, prostaglandin E1 and atorvastatin three drugs in combination.